ElevateBio’s BaseCamp facility will provide “bench-to-bedside” services to its portfolio and partner companies – as the demand for cell and gene therapy CMOs “far outweighs the capacity,” says CEO.
Lonza and Emerald Health enter an agreement for the large-scale manufacturing of a synthetic derivative of CBD and its oral drug product for the treatment of MS and other CNS diseases.
Pressure BioSciences has launched a commercial biopharmaceutical contract service business after acquiring a protein therapeutics platform that it says reduces challenges and manufacturing costs of the growing drug market.
Thousand Oaks Biopharmaceuticals raised $45m in Series A financing, enabling the company to expand its CDMO and CMC services as well as its capabilities in global biologics development.
This second phase of the two-phase expansion project will increase the company’s bioanalytical capabilities at the site by 50% when the expansion is complete in 2020.
Sharp has signed a preferred partnerships agreement with an MA-based CMO to reduce “friction” for clients while decreasing the time, cost, and complexity of managing clinical trials.
The 5,000-square-foot expansion responds to client demand, says president Robert Lee: “The market for services is growing, yet the supply of CMOs interested in taking on these complex drug products is not.”
Pfizer CentreOne has recently expanded its fill-finish and highly potent solid oral dose service offerings at two of its contract manufacturing facilities as it aims to fulfill a promise to grow its capabilities.
Mayne Pharma has started adding contract manufacturing capacity at its site in North Carolina in an project that will also see it consolidate US distribution operations.
Quality and IP issues are driving firms back to the US and Europe for their contract manufacturing according to experts, but Kemwell says there are still opportunities for Indian CMOs.
Perrigo Company has reported a 40% drop in contract manufacturing revenue year-on-year due to a key client, assumed by analysts to be J&J, returning to OTC in-house production.
Active pharmaceutical ingredient production will be the driving factor behind a predicted boom in the pharmaceutical contract manufacturing market, according to Visiongain.
The financial flexibility and quality standards of Indian CMOs should be enough to stave off competition from newer global contract manufacturing hubs, according to market research company RNCOS.
Xcellerex is building a second cGMP FlexFactory biomanufacturing facility to support clients transitioning to their own plants and provide contract manufacturing services.
Overcapacity in pharmaceutical manufacturing around the world means that smaller drugmakers sometimes set themselves up as contract manufacturers in order to provide an additional revenue stream and avoid standing plants idle.
A study is predicting biologics will drive contract manufacturing to new heights, with Gilead Sciences reported to be the latest biotech to pursue production partnerships in India.
in-PharmaTechnologist.com’s latest round up of developments in contract manufacturing includes Therapure’s launch and facility expansions by Hollister-Stier, West and Dow.
Sancilio & Co (SCI) says that its new contract manufacturing plant in Riviera Beach, Florida can provide pharmaceutical manufacturers with small batch production capacity for drug tablets and capsules.
British contract manufacturing organisation (CMO) NextPharma
Technologies has announced a €30m fundraising round and the
acquisition of Bioserv, another CMO based in the US.
Actavis has waded further into India and picked up new contract
manufacturing capabilities along the way with the purchase of a
division of Sanmar Specialty Chemicals (SSCL).
Baxter is expanding its lyophilisation capacity at its German
facility to support future growth of its contract manufacturing
business for anti-cancer drugs.
Firms engaging in both in-house and contract pharma manufacturing
generally display inferior performance compared to manufacturers
conducting only in-house production, according to new research.
A good selection process, with a realistic set of selection
criteria is essential when looking for the right contract
manufacturing partner, according to a new Datamonitor report.
Offshoring contract manufacturing is not the only option for large
pharma firms looking to drive productivity and efficiency gains in
drug manufacturing, warns a new report from independent market
analyst Datamonitor.
Despite its consolidation, the competitive consumable sector still
offers potential for rapid growth and better profits in the
biopharmaceutical industry, while contract bioprocessing services
will be increasingly in demand, according...
Pharmaceutical manufacturer Patheon has reaffirmed its dominant
position in the outsourcing market with the announcement of a
five-year master supply agreement with drug giant Merck.
Oman Pharmaceutical Products (OPP) has entered its first
outsourcing partnership in Europe with Finnish company
Dragenopharm, providing the first step in its strategy to offer
contract manufacturing services globally.
Patheon has received the 2005 Contract Manufacturing Company of the
Year Award from consultancy firm Frost & Sullivan, in
recognition of its customer service and innovative market growth
strategies.
Pharmaceutical companies are increasingly looking to retain their
internal focus on research and development (R&D) and marketing
while outsourcing their manufacturing processes, thus fueling a
growing demand for the manufacturing...
A desire by pharmaceutical companies to concentrate their resources
on marketing products, rather than production and drug discovery,
will drive global revenues for contract manufacturing and research
to nearly $168bn (€128bn) by...
Medivative Technologies, a contract manufacturing and process
engineering services supplier to the life sciences and medical
device industries, has just been cleared for operations by the US
Food and Drug Administration (FDA).
Japan's Sumitomo Chemical is absorbing its wholly-owned Sumika Fine
Chemicals subsidiary and combining it with its own activities in
this area to bolster its role as a supplier of pharmaceutical
chemicals.
